Oslo, Norway, 25 August 2026 – Circio Holding ASA (OSE: CRNA), a biotechnology company developing novel circular RNA expression technology for gene and cell therapy, will host a live webcast from its R&D headquarter in Stockholm, Sweden, at 10:00am CEST on Tuesday 1 September 2026.
In the webcast, CEO Dr. Erik D Wiklund and CFO Dr. Lubor Gaal will provide a corporate update including a summary of first half 2026 financials and an overview of Circio´s extensive business development activities. CTO Dr. Thomas B Hansen will present the most recent circVec pre-clinical results, including promising new in vivo data generated in heart and CNS gene therapy, as well as advances on the in vivo CAR-T program.
The first half year 2026 report will be published on 31 August 2026, and further information and presentation materials will be published ahead of the webcast on 1 September 2026.
The webcast will be held in English. Questions can be submitted in advance by email to Erik D Wiklund: erik.wiklund@circio.com or directly in the live webcast.
Time: 10:00 CEST on Tuesday 1 September 2026
Click here to access Teams webcast
Meeting ID: 343 877 779 042 528
Passcode: MD3Pv2nP
A recording of the webcast will be made available on the Circio webpage and the presentation materials are attached hereto.